Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma (Q44968984)

7 December 2017

Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma (English)

1 reference

7 December 2017

Giuditta Cuccuru

1

1 reference

7 December 2017

Cinzia Lanzi

2

1 reference

7 December 2017

Giuliana Cassinelli

3

1 reference

7 December 2017

Graziella Pratesi

4

1 reference

7 December 2017

Monica Tortoreto

5

1 reference

7 December 2017

Giovanna Petrangolini

6

1 reference

7 December 2017

Ettore Seregni

7

1 reference

7 December 2017

Antonia Martinetti

8

1 reference

7 December 2017

Diletta Laccabue

9

1 reference

7 December 2017

Chiara Zanchi

10

1 reference

7 December 2017

Franco Zunino

11

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

Journal of the National Cancer Institute

7 December 2017

1 reference

7 December 2017

96

1 reference

7 December 2017

13

1 reference

7 December 2017

1006-1014

1 reference

Medullary carcinoma of the thyroid gland

7 December 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

The RET proto-oncogene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

The GDNF/RET signaling pathway and human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

Smart drugs: tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

New colorimetric cytotoxicity assay for anticancer-drug screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

Preserved phosphorylation of RET receptor protein in spinal motor neurons of patients with amyotrophic lateral sclerosis: an immunohistochemical study by a phosphorylation-specific antibody at tyrosine 1062.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

STI571 (Gleevec) as a paradigm for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

STI571: a paradigm of new agents for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJH184

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJH184

1 reference

7 December 2017

1 reference